Which outcomes should be measured in hand eczema trials? Results from patient interviews and an expert survey.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
05
08
2022
accepted:
16
01
2023
medline:
15
5
2023
pubmed:
26
1
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Hand eczema (HE) is a common skin disease characterized by itch, pain and visible skin changes such as fissures, erythema and vesicles. It is not yet clear which outcome domains are most important for patients. The Hand Eczema Core Outcome Set (HECOS) initiative is developing a consented set of core domains and suitable measurement instruments for the future application in all HE trials. This includes an online Delphi survey about core domains, which requires a 'Long List' of all domains that might be important to measure. To compile a 'Long List' of candidate outcome domains for therapeutic HE trials with suggestions from patients and experts. First, 60 patients with chronic HE were interviewed at seven study sites in Croatia, Denmark, Germany, the Netherlands and Spain. Patients were asked about domains that were important from their perspectives. Second, 185 HE experts were invited by email to complete an online survey. With an open question, they were asked to suggest up to six domains. Suggestions were provided by 58 patients and 82 experts. Most patients and experts suggested to measure the domains 'signs', 'symptoms' and 'HE-related quality of life'. Specifically, >25% of patients said that less itch, pain or fissures indicated a successful treatment. Among experts, >25% suggested 'itch' and 'ability to work' as core sub-domains. Further outcomes from the domains 'HE control over time', 'patient-reported treatment experience' and 'skin barrier function' were mentioned. 'Itch' was rated high among patients with HE and professional HE experts. While patients emphasized fissures as important, experts underlined the ability to work. This investigation allowed us to define a 'Long List' of 7 candidate outcome domains with 58 sub-domains. From this list, a panel of stakeholders will select core domains during an online Delphi survey.
Sections du résumé
BACKGROUND
BACKGROUND
Hand eczema (HE) is a common skin disease characterized by itch, pain and visible skin changes such as fissures, erythema and vesicles. It is not yet clear which outcome domains are most important for patients. The Hand Eczema Core Outcome Set (HECOS) initiative is developing a consented set of core domains and suitable measurement instruments for the future application in all HE trials. This includes an online Delphi survey about core domains, which requires a 'Long List' of all domains that might be important to measure.
OBJECTIVES
OBJECTIVE
To compile a 'Long List' of candidate outcome domains for therapeutic HE trials with suggestions from patients and experts.
METHODS
METHODS
First, 60 patients with chronic HE were interviewed at seven study sites in Croatia, Denmark, Germany, the Netherlands and Spain. Patients were asked about domains that were important from their perspectives. Second, 185 HE experts were invited by email to complete an online survey. With an open question, they were asked to suggest up to six domains.
RESULTS
RESULTS
Suggestions were provided by 58 patients and 82 experts. Most patients and experts suggested to measure the domains 'signs', 'symptoms' and 'HE-related quality of life'. Specifically, >25% of patients said that less itch, pain or fissures indicated a successful treatment. Among experts, >25% suggested 'itch' and 'ability to work' as core sub-domains. Further outcomes from the domains 'HE control over time', 'patient-reported treatment experience' and 'skin barrier function' were mentioned.
CONCLUSION
CONCLUSIONS
'Itch' was rated high among patients with HE and professional HE experts. While patients emphasized fissures as important, experts underlined the ability to work. This investigation allowed us to define a 'Long List' of 7 candidate outcome domains with 58 sub-domains. From this list, a panel of stakeholders will select core domains during an online Delphi survey.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199-1206Subventions
Organisme : European Academy of Dermatology and Venereology
ID : PPRC_2019_27
Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Quaade AS, Simonsen AB, Halling AS, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis. Contact Dermatitis. 2021;84(6):361-74.
Grant L, Seiding Larsen L, Burrows K, Belsito DV, Weisshaar E, Diepgen T, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692-706.
Ruppert L, Apfelbacher C, Molin S, Bauer A, Mahler V, Schmitt J, et al. Itching in patients with chronic hand eczema: data from the CARPE registry. Dermatology. 2014;229(2):146-53.
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-78.
Christoffers WA, Coenraads PJ, Svensson A, Diepgen TL, Dickinson-Blok JL, Xia J, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4:CD004055.
Saldanha IJ, Dodd S, Gorst SL, Williamson PR. More than half of systematic reviews have relevant core outcome sets. J Clin Epidemiol. 2021;136:168-79.
Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18(Suppl 3):280.
Rönsch H, Apfelbacher C, Brans R, Matterne U, Molin S, Ofenloch R, et al. Which outcomes have been measured in hand eczema trials? A systematic review. Contact Dermatitis. 2019;80(4):201-7.
Rönsch H, Apfelbacher C, Brans R, Ofenloch R, Schuttelaar MLA, Weisshaar E, et al. Protocol for the development of a core domain set for hand eczema trials. J Eur Acad Dermatol Venereol. 2020;34(12):2871-6.
Lange T, Kottner J, Weberschock T, Hahnel E, Apfelbacher C, Brandstetter S, et al. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology-specific outcome taxonomy. J Eur Acad Dermatol Venereol. 2021;35(2):523-35.
Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018;96:84-92.
Dirr MA, Alam M, Apfelbacher C, Drewitz KP, Kang BY, Munblit D, et al. Improvements and advances in core outcome set methodology: proceedings of the CS-COUSIN & COMFA joint meeting. Arch Dermatol Res. 2022;1-5.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302-7.
Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-oriented eczema measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising outcome measures for eczema (HOME) statement. Br J Dermatol. 2017;176(4):979-84.
Pattinson RL, Trialonis-Suthakharan N, Gupta S, Henry AL, Lavallée JF, Otten M, et al. Patient-reported outcome measures in dermatology: a systematic review. Acta Derm Venereol. 2021;101(9):adv00559.
Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesthet Dermatol. 2015;8(11):19-27.
Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161(2):397-403.
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-40.
Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol. 2020;183(3):524-36.
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367-76.
Fortino V, Wisgrill L, Werner P, Suomela S, Linder N, Jalonen E, et al. Machine-learning-driven biomarker discovery for the discrimination between allergic and irritant contact dermatitis. Proc Natl Acad Sci USA. 2020;117(52):33474-85.
Han X, Krempski JW, Nadeau K. Advances and novel developments in mechanisms of allergic inflammation. Allergy. 2020;75(12):3100-11.
Koppes SA, Brans R, Ljubojevic Hadzavdic S, Frings-Dresen MH, Rustemeyer T, Kezic S. Stratum corneum tape stripping: monitoring of inflammatory mediators in atopic dermatitis patients using topical therapy. Int Arch Allergy Immunol. 2016;170(3):187-93.
Langbroek GB, Wolkerstorfer A, Horbach SER, Spuls PI, Kelly KM, Robertson SJ, et al. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project). J Eur Acad Dermatol Venereol. 2021;35(9):1888-95.